Cases & Deals

  • Home
  • Practices
  • Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirus

Share

Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirus

May 2020

Client(s) Shanghai Junshi Biosciences Co., Ltd.

Jones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus. Junshi and Lilly will collaborate to conduct clinical trials using antibodies controlled by Junshi and licensed to Junshi from a research institute in China and sublicensed to Lilly. Lilly will conduct trials and commercialization outside of Greater China and Junshi will do so within Greater China.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.